Cargando…
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
BACKGROUND: Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations initially respond to first-generation EGFR inhibitors; however, the efficacy of these drugs is limited by acquired resistance driven by the EGFR (T790M) mutation. The discovery of third-generation EGFR inhibitors...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218543/ https://www.ncbi.nlm.nih.gov/pubmed/32404161 http://dx.doi.org/10.1186/s12943-020-01202-9 |